Rome Therapeutics, Inc.

Based in the US, Rome Therapeutics develops innovative therapies targeting the dark genome, focusing on reversing disease progression linked to genetic factors through advanced data science and proprietary therapeutic solutions. Rome Therapeutics is a biotechnology firm founded in 2020, located in Boston, US, specializing in treatments for diseases associated with the dark genome. The company has not undergone significant business pivots or changes since its inception. Founded by Benjamin Greenbaum and David Ting, the current CEO is Rosana Kapeller.

Rome Therapeutics has successfully raised USD 72. 00 mn in SERIES B funding on June 6, 2023, with notable investors including Johnson & Johnson Innovation, Bristol-Myers Squibb, and Andreessen Horowitz. The total amount raised by the company to date is USD 72. 00 mn, and it currently holds a valuation of USD 252.

57 mn. ROME Therapeutics specializes in pioneering innovative treatments that target the previously underexplored regions of the human genome, referred to as the dark genome. Their core product offerings focus on the development of proprietary therapies that inhibit LINE-1 reverse transcriptase, a protein linked to various diseases including autoimmune disorders, cancer, and neurodegenerative conditions. Their lead program aims to leverage insights gained from their advanced data science platform and extensive knowledge of repeat biology to create breakthrough therapies.

The company’s products are still in the preclinical stages, with promising results demonstrated in models of Parkinson’s disease and other related conditions. ROME Therapeutics is primarily focused on markets in North America and Europe, targeting healthcare providers, research institutions, and pharmaceutical partners engaged in developing next-generation treatments for serious health challenges. Information regarding the revenue structure of ROME Therapeutics is not publicly disclosed; however, the company engages in transactions through partnerships with research institutions, pharmaceutical companies, and healthcare providers. These partnerships may involve collaborative research agreements, where ROME Therapeutics provides access to its proprietary LINE-1 inhibitors in exchange for funding or shared intellectual property rights.

Additionally, the company explores B2B arrangements for product development and testing, potentially leading to licensing agreements once the therapies are commercialized. The revenue model may include milestone payments, royalties on future sales, or other forms of compensation as products advance through clinical development and into the market. In June 2023, Rome Therapeutics, Inc. raised USD 72 mn in SERIES B funding, intended to advance its LINE-1 reverse transcriptase (RT) inhibitor medication candidate through early clinical trials, including Phase 1 tests to assess safety and determine optimal dosing.

The company plans to launch new products targeting the dark genome and is focused on expanding its presence in North America and Europe, particularly targeting healthcare providers and research institutions. The funding will support the early clinical trials necessary to demonstrate the efficacy of the therapies, contributing to the company's future growth.